Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. We are also developing OP-3136, our lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study.

Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

For more information, please visit www.olema.com.

Please join us in this fight by making your donation today.  

Onto Something Big, Together!